Literature DB >> 29321107

Can I Send This Patient with Stroke Home? Strategies Managing Transient Ischemic Attack and Minor Stroke in the Emergency Department.

Bernard P Chang1, Sara Rostanski2, Joshua Willey3, Benjamin Kummer3, Eliza Miller3, Mitchell Elkind3.   

Abstract

BACKGROUND: While transient ischemic attack and minor stroke (TIAMS) are common conditions evaluated in the emergency department (ED), there is controversy regarding the most effective and efficient strategies for managing them in the ED. Some patients are discharged after evaluation in the ED and cared for in the outpatient setting, while others remain in an observation unit without being admitted or discharged, and others experience prolonged and potentially costly inpatient admissions. OBJECTIVE OF THE REVIEW: The goal of this clinical review was to summarize and present recommendations regarding the disposition of TIAMS patients in the ED (e.g., admission vs. discharge). DISCUSSION: An estimated 250,000 to 300,000 TIA events occur each year in the United States, with an estimated near-term risk of subsequent stroke ranging from 3.5% to 10% at 2 days, rising to 17% by 90 days. While popular and easy to use, reliance solely on risk-stratification tools, such as the ABCD2, should not be used to determine whether TIAMS patients can be discharged safely. Additional vascular imaging and advanced brain imaging may improve prediction of short-term neurologic risk. We also review various disposition strategies (e.g., inpatient vs. outpatient/ED observation units) with regard to their association with neurologic outcomes, such as 30-day or 90-day stroke recurrence or new stroke, in addition to other outcomes, such as hospital length of stay and health care costs.
CONCLUSIONS: Discharge from the ED for rapid outpatient follow-up may be a safe and effective strategy for some forms of minor stroke without disabling deficit and TIA patients after careful evaluation and initial ED workup. Future research on such strategies has the potential to improve neurologic and overall patient outcomes and reduce hospital costs and ED length of stay.
Copyright © 2017 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  TIA; clinical review; minor stroke

Mesh:

Year:  2018        PMID: 29321107      PMCID: PMC6446571          DOI: 10.1016/j.jemermed.2017.12.015

Source DB:  PubMed          Journal:  J Emerg Med        ISSN: 0736-4679            Impact factor:   1.484


  5 in total

1.  Safety and Feasibility of a Rapid Outpatient Management Strategy for Transient Ischemic Attack and Minor Stroke: The Rapid Access Vascular Evaluation-Neurology (RAVEN) Approach.

Authors:  Bernard P Chang; Sara Rostanski; Joshua Willey; Eliza C Miller; Steven Shapiro; Rachel Mehendale; Benjamin Kummer; Babak B Navi; Mitchell S V Elkind
Journal:  Ann Emerg Med       Date:  2019-07-17       Impact factor: 5.721

2.  Are patients afraid to go home? Disposition preferences after transient ischaemic attack and minor stroke.

Authors:  Bernard P Chang; Talea Cornelius; Joshua Willey; Donald Edmondson; Mitchell Sv Elkind; Ian M Kronish
Journal:  Emerg Med J       Date:  2020-01-28       Impact factor: 2.740

Review 3.  Evaluation of Transient Ischemic Attack and Minor Stroke: A Rapid Outpatient Model for the COVID-19 Pandemic and Beyond.

Authors:  Paul M Wechsler; Neal S Parikh; Linda A Heier; Evelyn Ruiz; Matthew E Fink; Babak B Navi; Halina White
Journal:  Neurohospitalist       Date:  2021-03-29

4.  Ischemic stroke with a preceding Trans ischemic attack (TIA) less than 24 hours and thrombolytic therapy.

Authors:  Nicolas Poupore; Dan Strat; Tristan Mackey; Ashley Snell; Thomas Nathaniel
Journal:  BMC Neurol       Date:  2020-05-19       Impact factor: 2.474

5.  Safety and Hospital Costs Averted Using a Rapid Outpatient Management Strategy for Transient Ischemic Attack and Minor Strokes: The RAVEN Clinic.

Authors:  Steven D Shapiro; Amelia K Boehme; Bernard P Chang; Eliza C Miller; Joshua Willey; Mitchell S V Elkind
Journal:  Neurohospitalist       Date:  2020-11-05
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.